Ani Pharmaceuticals (ANIP) Gains from Sales and Divestitures (2017 - 2023)

Ani Pharmaceuticals has disclosed Gains from Sales and Divestitures across 7 years of filings, most recently posting $235000.0 for Q1 2023.

• Gains from Sales and Divestitures for Q1 2023 came in at $235000.0, up 45.96% year-over-year; the trailing twelve-month figure through Mar 2023 was $235000.0 (up 45.96% YoY), and the FY2022 annual result was $245000.0, up 96.0% from the prior year.
• Gains from Sales and Divestitures came in at $235000.0 for Q1 2023 at Ani Pharmaceuticals, down from $245000.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $245000.0 in Q4 2022 to a low of $34000.0 in Q1 2021.
• The 5-year median for Gains from Sales and Divestitures is $125500.0 (2021), against an average of $126937.5.
• Across the five-year window, Gains from Sales and Divestitures sank 30.61% in 2021 and soared 373.53% in 2022, its largest moves.
• Ani Pharmaceuticals' Gains from Sales and Divestitures stood at $42000.0 in 2019, then soared by 202.38% to $127000.0 in 2020, then retreated by 1.57% to $125000.0 in 2021, then surged by 96.0% to $245000.0 in 2022, then slipped by 4.08% to $235000.0 in 2023.
• The last three Gains from Sales and Divestitures figures came in at $235000.0 (Q1 2023), $245000.0 (Q4 2022), and $234000.0 (Q3 2022), per Business Quant data.